FDA
-
-
-
-
-
-
-
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
-
-
-
-
-
-
-
Pliant Therapeutics (PLRX) Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
Pliant Therapeutics Inc. (PLRX) Appoints Delphine Imbert as Chief Technical Officer
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
-
-
-
-
-
-
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activ
-
-
-
-
-
-
-
Pliant Therapeutics (PLRX) Reports Positive Topline Data from a Phase 2a Collagen PET Imaging Trial
-
322,940 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

